Explore VistaGen Therapeutics, Inc.'s Q4 2024 report, highlighting cash position, accumulated deficit, and strategic recommendations for investors amid ongoing operating losses.
Explore Vistagen Therapeutics' 8-K filing detailing significant updates as of September 23, 2024. Stay informed on corporate developments and stock insights.
Explore Vistagen Therapeutics' latest 8-K report filed on January 14, 2025, detailing crucial updates and corporate changes that impact VTGN investors.
Explore Vistagen Therapeutics' Form 8-K filed on January 10, 2025, detailing significant events and stock information. Stay informed on VTGN's latest developments.